06:59 AM EDT, 09/08/2026 (MT Newswires) -- BofA Global Research views upcoming detailed trial results for Novartis' (NOVN.SW) remibrutinib in multiple sclerosis as a critical catalyst after the late-stage misses of myotonic dystrophy type 1 candidate, del-desiran, and cardiovascular drug pelacarsen. Analysts said Tuesday that Novartis needed a multi-asset win to clear its post-2030 patent cliff, but with pelacarsen and del-desiran both striking out, remibrutinib is now the last high-profile candidate standing. "Post-pelacarsen and del-des failures, detailed Remi MS data (MS Toronto 23rd Oct) now needs to be towards the upside case. While Remi MS headline hit, stock move not reflecting full [net present value] given enough questions ([annualized relapse rate] no mention clinically meaningful, extent progression benefit vs [cluster of differentiation 20], details on 2 deaths, broader safety). Base case $3bn peak sales in MS with detailed data to inform on upside (possible >$5bn). Best cross-trial comparison is Kesimpta which demonstrated a [confirmed disability progression] of 34% vs Aubagio. It is unclear whether remibrutinib is meaningfully better than fenebrutinib's 23% CDP benefit," the research firm added. Against this backdrop, BofA maintained its buy rating and price objective of 150 francs on the stock.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.